222 related articles for article (PubMed ID: 21152241)
1. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Pal SK; Twardowski P; Sartor O
Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
4. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
5. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
6. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Figg WD; Figg WD
Cancer Biol Ther; 2010 Dec; 10(12):1233-4. PubMed ID: 21107022
[TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
8. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
Keating GM
Drugs Aging; 2013 May; 30(5):359-65. PubMed ID: 23532557
[TBL] [Abstract][Full Text] [Related]
9. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
10. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.
McKeage K
Drugs; 2012 Jul; 72(11):1559-77. PubMed ID: 22818017
[TBL] [Abstract][Full Text] [Related]
12. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S
Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel, a new taxane with favorable properties.
Bouchet BP; Galmarini CM
Drugs Today (Barc); 2010 Oct; 46(10):735-42. PubMed ID: 21076710
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
[TBL] [Abstract][Full Text] [Related]
16. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
Mita AC; Figlin R; Mita MM
Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116
[TBL] [Abstract][Full Text] [Related]
18. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
Altavilla A; Iacovelli R; Procopio G; Alesini D; Risi E; Campennì GM; Palazzo A; Cortesi E
Cancer Biol Ther; 2012 Sep; 13(11):1001-8. PubMed ID: 22825325
[TBL] [Abstract][Full Text] [Related]
19. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
20. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
